Chronic Refractory Cough
Respiratory
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
GSKBLU-5937
Avalo TherapeuticsFP01
Clinical Trials (2)
Total enrollment: 68 patients across 2 trials
A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough
Start: Jul 2019Est. completion: Apr 202068 patients
Phase 2Terminated
An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough
Start: Nov 2012Est. completion: Sep 2013
Phase 2Completed
Related Jobs in Respiratory
Regional Gene Therapy Consultant - Upper Midwest (IL/WI/MN)
Krystal Biotech
1h ago
$185K - $215K/yr
Regional Gene Therapy Consultant - Southwest (CO/AZ/NM/UT)
Krystal Biotech
1h ago
$185K - $215K/yr
Ausbildung zum Pharmakanten (m/w/d)
Ferring Pharmaceuticals
Kiel, Germany
Yesterday
Marketing Intern – Vertex Iberia (Spain)
Vertex Pharmaceuticals
Madrid, Spain
Yesterday
Sales Rep Neurology Region Leipzig, Halle, Gera, Jena, Weimar DE_G2M110105 - befristet bis 31.03.2027 (all genders)
Sanofi
Berlin
Yesterday
Laboratory Assistant (m/w/d)
Ferring Pharmaceuticals
Kiel, Germany
2d ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space